Detection of T lymphocyte subsets and mIL-2R on surface of PBMC in patients with hepatitis B

Table 2 Detection of T lymphocyte subsets and mIL-2R in PBMC with HBV-DNA (+) before and after induced with PHA (^-x±s, %)

Group	n	CD3+	CD4+	CD8+	CD4+/CD8+	mIL-2R
						Silent	Induced
Control	30	65.96 ± 6.54	41.73 ± 6.40	30.02 ± 4.54	1.44 ± 0.31	4.52 ± 1.49	37.95 ± 3.00
Anti-HBs (+)	10	66.34 ± 5.16	42.82 ± 6.52	29.03 ± 4.50	1.51 ± 0.27	5.06 ± 1.45	40.26 ± 3.10
NBD	20	65.80 ± 6.92	41.20 ± 6.36	30.45 ± 4.62	1.39 ± 0.33	4.24 ± 1.52	36.30 ± 2.95
Hepatitis B	196	42.20 ± 6.01	38.17 ± 5.93	39.86 ± 6.36	0.91 ± 0.28	3.47 ± 1.55	34.03 ± 2.94
HBV-DNA (+) of PBMC	118	39.57 ± 7.11a	34.36 ± 7.16b	37.82 ± 6.54c	0.88 ± 0.33d	2.82 ± 1.62e	31.56 ± 3.00f
HBV-DNA (-) of PBMC	78	44.36 ± 5.43a	40.75 ± 5.87b	41.72 ± 6.21c	0.99 ± 0.27d	3.85 ± 1.47e	35.84 ± 2.83f

^at = 5.3466, ^aP < 0.001.

^bt = 6.8525, ^bP < 0.01.

^ct = 4.2414, ^cP < 0.001.

^dt = 2.5641, ^dP < 0.05.

^et = 4.6355, ^eP < 0.001.

^ft = 10.0352, ^fP < 0.001. NBD: Normal blood donors.